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The C-type lectin DC-SIGN mediates the capture and transfer of simian immunodeficiency virus (SIV) from macaque dendritic cells
(DCs) to permissive T-cells. To further identify the determinants in macaque DC-SIGN required for capture and transfer of virus, we created
mutants containing deletions or point mutations in the extracellular domains, and tested their ability to capture and transmit SIV. We found
that SIV bound to the carbohydrate recognition domain (CRD) of macaque DC-SIGN via the envelope protein. In addition, deleting the C-
terminal half of the CRD, or mutating amino acids within this region that contact Ca2+ or mannose, disrupted virion capture activity.
However, an N-terminal CRD deletion mutant was capable of binding SIV, indicating that this region was not necessary for binding. Finally,
deletion of the neck domain also reduced the capacity for macaque DC-SIGN to capture SIV. Interestingly, ICAM-3, the cellular ligand for
DC-SIGN, did not bind to any of the DC-SIGN mutants, including mutants with amino acid changes in the N-terminal region of the CRD.
These data suggest that the binding sites for SIVand ICAM-3 may be distinct but overlapping. Together, the data demonstrate the importance
of both the neck and the CRD of macaque DC-SIGN for efficient capture of SIV and binding to ICAM-3.
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Myeloid-derived dendritic cells (DCs) are believed to
play a major role in human immunodeficiency virus (HIV)
and simian immunodeficiency virus (SIV) infection and
replication in CD4+ T-cells. HIV is captured by DCs through
an interaction with mannose C-type lectin receptors
expressed on the surface of DCs (Turville et al., 2002).
The most well characterized of these receptors is DC-SIGN,
which binds HIV via the envelope surface glycoprotein
(Env SU) and transmits it to susceptible cells (Curtis et
al., 1992; Geijtenbeek et al., 2000a, 2000b). Although the
discovery of DC-SIGN provides an explanation for how
DCs capture and transmit virus, the significance of DC-
SIGN for HIV infection and replication in the host remains
unclear. Because questions about HIV transmission and
pathogenesis are best addressed using the SIV macaque0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: jkimata@bcm.tmc.edu (J.T. Kimata).model, we and others have recently cloned and character-
ized DC-SIGN from rhesus (rh) and pig-tailed (pt) mac-
aques and shown them to be highly homologous with
human DC-SIGN (Baribaud et al., 2001; Wu et al., 2002).
In addition, we demonstrated that pig-tailed macaque mono-
cyte-derived DCs efficiently capture and transfer SIV to
CD4+ T-cells in a ptDC-SIGN-dependent manner (Yu
Kimata et al., 2002). Thus, the SIV pig-tailed macaque
model may be useful for investigating the significance of
DC-SIGN in HIV infection.
DC-SIGN contains several structural domains that may
be necessary for the capture and transfer of virus as well as
for interactions with its cellular ligand on T-cells, ICAM-3.
First, the extracellular calcium-dependent carbohydrate rec-
ognition domain (CRD) mediates binding to ICAM-3 and
the HIV Env SU protein. These interactions are believed to
be dependent upon high-mannose residues in Env SU
because treatment with Endo-h-N-glucosaminidase H or
competition with mannan decrease binding to DC-SIGN
(Geijtenbeek et al., 2000a; Hong et al., 2002; Lin et al.,
2003). However, another study showed that deglycosylated
HIV Env SU could still bind DC-SIGN, suggesting that N-
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binding (Geijtenbeek et al., 2002). Additionally, the deter-
minants in DC-SIGN necessary for binding ICAM-3 or
either the HIV or the SIV Env SU proteins remain poorly
characterized. Second, according to biochemical and struc-
tural data, the tandem repeat sequences (neck domain) of
DC-SIGN may be required for oligomerization of DC-SIGN
molecules (Mitchell et al., 2001). Although the role of the
neck domain for interactions with HIV or ICAM-3 is
unclear, it is interesting to note that a macaque homolog
of DC-SIGN (CD209L2), which encodes a short neck
domain, has reduced ability to capture and transfer HIV
and SIV, suggesting that the neck region may play a key role
in efficient virus transmission (Bashirova et al., 2003).
Finally, the intracellular tail domain contains motifs that
mediate internalization of DC-SIGN. Whether internaliza-
tion of the virus by DC-SIGN is necessary to enhance viral
infectivity remains unclear (Kwon et al., 2002; Sol-Foulon
et al., 2002). Further characterization of the determinants in
DC-SIGN would provide insight into how it mediates viral
infection in trans.
In the present study, we examined the role that the ptDC-
SIGN extracellular domains (neck and CRD) play in bind-
ing SIV and ICAM-3. Our data indicate that both the neck
and CRD of ptDC-SIGN have critical roles in capture of
SIV and binding to ICAM-3. They also suggest that SIV and
ICAM-3 may recognize distinct but overlapping sites in the
ptDC-SIGN CRD.Fig. 1. Capture of SIV variant viruses by ptDC-SIGN. (A) ptDC-SIGN
mediated binding of SIV variant viruses. Cell-associated SIV p27gag
antigen is shown as a percentage of the amount of virus (SIVmneCl8,
SIVmne170, or SIVmne027) added to the cell cultures. (B) Inhibition of
virion capture by EGTA or mannan. The p27gag antigen levels for virus
alone were normalized to 100% and the relative values obtained in the
presence of mannan, EGTA, or control transfected cells are shown. 293T
cells were transfected with the expression vector pHM6 without insert
(control) to monitor background binding or with the ptDC-SIGN cDNA
insert (ptDC-SIGN). The experiments in A and B were performed in
triplicate and the data are representative of at least two independent
experiments. The average amount of p27gag antigen bound to cells is
shown F SEM.Results
Capture of SIV variants by ptDC-SIGN
Previously, we and others demonstrated that transmis-
sion of SIV to permissive cells by rhesus or pig-tailed
macaque DC-SIGN could be inhibited by mannan (Bar-
ibaud et al., 2001; Wu et al., 2002; Yu Kimata et al.,
2002). However, none of the studies directly examined
SIV binding to macaque DC-SIGN. In addition, we found
that SIVmne variants display different sensitivities to
antibody-mediated inhibition of virus transfer to permis-
sive cell types (Yu Kimata et al., 2002). Because the
variant viruses differ in the number of N-linked glycosyl-
ation sites within their Env SU proteins (Kimata and
Overbaugh, 1997; Kimata et al., 1998, 1999; Overbaugh
et al., 1991), we hypothesized that sensitivity to capture
neutralizing anti-ptDC-SIGN antibodies may be due to
differences in the level of binding between the viruses and
ptDC-SIGN. Therefore, we investigated whether these
SIV variants differ in their ability to be captured by
ptDC-SIGN. We also examined whether the SIV Env
SU protein is specifically required for this interaction to
occur.
To examine whether there were differences in the ability
of SIVmne variants to bind ptDC-SIGN, we measured theamount of each virus captured by ptDC-SIGN expressed on
293T cells. In comparison to cells transfected with a control
vector, virion binding to ptDC-SIGN-expressing cells was
enhanced 2.5- to 5-fold (Fig. 1A). Specifically, 7.9% of
SIVmneCl8 remained associated with ptDC-SIGN-express-
ing cells whereas 8.9% and 5% of SIVmne170 and
SIVmne027, respectively, remained attached to ptDC-
SIGN-expressing cells. Typically, less than 2% of the
viruses remained associated with cells transfected with the
control plasmid. In agreement with previous studies on HIV
and human DC-SIGN (Geijtenbeek et al., 2000a; Pohlmann
et al., 2001a), binding of SIV to ptDC-SIGN was dose
dependent (data not shown). These data indicate that
SIVmne attachment to cells is enhanced by ptDC-SIGN
and there is little difference in binding of the different
SIVmne variants to ptDC-SIGN.
To further characterize the interactions between ptDC-
SIGN and the SIV variants, we examined whether
pretreatment of the ptDC-SIGN-expressing cells with
Fig. 3. Capture of SIV by ptDC-SIGN deletion mutants. 293T cells
transfected with each of the ptDC-SIGN deletion constructs (wild-type
ptDC-SIGN, DCRD232 – 381, DCRD291 – 381, DCRD232 – 290,
DCRD291–332, and DNECK78–224) or a control plasmid (pHM6) were
incubated with SIVmne170 or DMEM complete, and the amount of virions
bound to cells was determined as in Fig. 1. Virus captured by each mutant is
shown relative to wild-type ptDC-SIGN after correcting for background
binding. A value of 0 indicates that there was no significant binding of virus
above background. The experiments were performed in triplicate and the
data are representative of at least two independent experiments. The
average amount of p27gag bound to each of the mutants is shown as a
percentage of that bound by wild-type ptDC-SIGN F SEM. The portion of
ptDC-SIGN present in each deletion mutant is shown relative to that in the
wild-type clone.
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EGTA, would interfere with attachment of the SIVmne
variants. Both mannan and EGTA reduced attachment of
each SIVmne variant by greater than 75% (Fig. 1B). This
is consistent with the binding activity of a C-type lectin.
The level of virion binding under these conditions was
similar to background levels observed with control trans-
fected cells. These data indicate that ptDC-SIGN interacts
with all three SIV variants through calcium-dependent
recognition of high-mannose residues, and they suggest
that the SIV association with ptDC-SIGN is mediated by
the CRD.
To determine whether the interaction between SIV and
ptDC-SIGN occurs through the viral Env SU protein, we
compared the relative amounts of wild-type SIVmne027 or
an Env deletion mutant (SIVmne027DEnv) that bound to
ptDC-SIGN. The removal of the Env SU reduced the ability
of SIVmne027 to bind ptDC-SIGN to background levels
(Fig. 2). Specifically, 2.6% of SIVmne027Denv bound to
ptDC-SIGN-expressing cells as compared to 7.9% of wild-
type virus. Less than 3% of the viruses remained bound to
control transfected cells. These data show that the Env of
SIV is the primary protein present on the surface of virions
mediating attachment to ptDC-SIGN.
Capture of SIV by ptDC-SIGN deletion mutants
To map determinants in ptDC-SIGN important for
binding SIV, we screened a panel of CRD deletion mutants
for virion capture activity. The mutants were created by
PCR and tagged with the hemagglutinin (HA) epitope.
Expression was confirmed by Western blot and fluores-Fig. 2. ptDC-SIGN capture of SIV requires viral envelope glycoprotein.
293T cells transfected with a control vector (pHM6) or ptDC-SIGN
expression vector were incubated with equal amounts of wild-type (wt)
SIVmne027, an Env deletion mutant (SIVmne027Denv), or DMEM
complete medium. SIV p27gag antigen bound is shown as a percentage
of the amount of antigen added to the cells. The experiments were
performed in triplicate and the data are representative of two independent
experiments. The average amount of p27gag antigen bound is shown F
SEM.cence activated cell sorting (FACS) (Yu Kimata et al.,
2002). Because the interaction between the different
SIVmne variants and ptDC-SIGN was similar, we exam-
ined virion capture by the mutant ptDC-SIGN molecules
using one of the variants, SIVmne170. Deletion of the
entire CRD (DCRD232–381) or the C-terminal 90 amino
acids (DCRD291–381) resulted in a complete loss of
virion capture activity (Fig. 3). Removal of the last nine
amino acids of ptDC-SIGN did not disrupt virion binding
(data not shown). By contrast, mutant DCRD232–290,
which is missing the N-terminal 58 amino acids of the
CRD, still retained 42% of the virion capture activity
compared to wild-type ptDC-SIGN. Deletion of 41 amino
acids from the central portion of the CRD (DCRD291–
332) also abolished SIV binding. Interestingly, this se-
quence includes amino acids E331, V328, and N326,
which are identical to residues (E354, V351, and N349)
in huDC-SIGN. These residues have been shown to be
important for CRD interactions with Ca2+ and mannose
(Feinberg et al., 2001). Together, these data show that the
C-terminal half of the ptDC-SIGN CRD contains important
determinants necessary for the capture of SIV, and they
provide further evidence that virions bind to the CRD via
high-mannose oligosaccharides.
Because CD209L2, a macaque DC-SIGN-related mole-
cule having a short neck domain, poorly transmits SIV
(Bashirova et al., 2003), we also examined whether trunca-
tion of the neck domain of ptDC-SIGN would abolish virion
capture activity. Although the neck deletion mutant
(DNECK78–224) encodes for the complete CRD, its ability
to capture SIV was reduced nearly 100-fold compared to
wild-type ptDC-SIGN (Fig. 3). This result indicates that the
neck domain of ptDC-SIGN modulates virion binding to the
CRD.
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and binding to ICAM-3
The capacity of the mutants to bind SIV could be
influenced by their level of expression on the surface of
cells. Therefore, we examined expression of each mutant by
FACS analysis using an anti-DC-SIGN monoclonal anti-
body (MAb) recognizing the neck domain (DC4; provided
by R.W. Doms; (Baribaud et al., 2001)) and anti-ptDC-
SIGN MAbs against the CRD (8C1 and 11C1; (Yu Kimata
et al., 2002)). Additionally, we performed FACS analysis to
examine the ability of each deletion mutant to bind recom-
binant ICAM-3. As we had previously demonstrated (Yu
Kimata et al., 2002), both the DC4 and 8C1 MAbs recog-
nized wild-type ptDC-SIGN expressed on 293T cells (Fig.
4). Additionally, the anti-CRD MAb 8C1 detected expres-
sion of the neck deletion mutant (DNECK78–224) but not
the CRD deletion mutant (DCRD232–290). A second anti-
CRD MAb, 11C1, also recognizes the DNECK78–224
mutant (data not shown and Yu Kimata et al., 2002). In
contrast, the anti-neck MAb DC4 detected surface expres-Fig. 4. Expression levels of DC-SIGN deletion mutants and regions of DC-SIGN es
neck domain (DNECK78–224), CRD (DCRD 232–290) deletion mutants, or a em
monoclonal antibodies (DC4 and 8C1; filled curves), recombinant human ICAM
secondary antibody as previously described (Yu Kimata et al., 2002). The cells wer
in at least four independent experiments.sion of the DCRD232–290 mutant but not the DNECK78–
224 mutant. The expression level of the neck deletion
mutant, DNECK78–224, was similar to wild-type ptDC-
SIGN. In contrast, the DCRD232–290 mutant was slightly
higher than that of wild-type ptDC-SIGN (MFI, 223 vs. 83),
although the percentage of positive cells was lower (51.1%
vs. 91.1%). These data indicate that although the reduced
capture activity of the DCRD232–290 mutant compared to
wild-type ptDC-SIGN may be due to expression on a lower
percentage of cells, the poor virion capture activity of the
DNECK78–224 mutant may not be simply due to de-
creased expression. Interestingly, the neck deletion mutant,
DNECK78–224, which had limited capacity to bind SIV
but retained reactivity with the anti-CRD 8C1 MAb, failed
to bind ICAM-3. Furthermore, despite having moderate SIV
binding activity, the CRD mutant, DCRD232–290 also did
not bind ICAM-3. Together, these data provide evidence
that the neck domain is essential for optimal ligand recog-
nition by the CRD. The data also suggest that there may be
differences between the determinants in the CRD required
for interacting with ICAM-3 and SIV.sential for binding ICAM-3. 293T cells transfected with wt ptDC-SIGN, the
pty control expression plasmid (pHM6) were incubated with anti-DC-SIGN
-3 (filled curves), or control antibodies (open curves) and a FITC labeled
e then analyzed using a BD FACScan analyzer. Similar results were obtained
Fig. 6. Transmission of SIV by ptDC-SIGN deletion mutants. 293T cells
transiently transfected with wt ptDC-SIGN, DNECK78–224, DCRD232–
290, or control (pHM6) expression plasmids were incubated with
SIVmne170 for 2 h. Following vigorous washing, cells were co-cultured
with CEMx174 cells for a 2-week period. At 3- to 4-day intervals,
supernatants were collected and viral replication was determined by
monitoring the levels of p27gag antigen by ELISA. The infections were
performed in triplicate, and the data are representative of two independent
experiments. The average p27gag levels are shown F SEM.
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To determine whether deletion of the neck domain
disrupted oligomerization of ptDC-SIGN, we differentially
tagged wild-type ptDC-SIGN and the neck deletion mutant
with HA- or myc-epitopes, coexpressed the HA- and myc-
tagged molecules, and examined association between the
tagged molecules using an immunoprecipitation/immuno-
blot procedure. When anti-HA MAb immunoprecipitates
from cells coexpressing wild-type HA- and myc-tagged
ptDC-SIGN molecules were probed by immunoblot analysis
with an anti-myc MAb, we detected a protein of 46.1 kDa,
corresponding to the predicted size of the ptDC-SIGN-myc
(Fig. 5, lane 3). This analysis also revealed that the HA-
tagged neck deletion mutant (DNECK-HA) bound the myc-
tagged molecule (DNECK-myc, 29.2-kDa protein; Fig. 5,
lane 5). Furthermore, the DNECK-myc mutant associated
with the HA-tagged wild-type ptDC-SIGN (Fig. 5, lane 7).
The myc-tagged ptDC-SIGN molecules were not detected in
protein-G sepharose used for preclearing the transfected cell
lysates (Fig. 5, lanes 4, 6, and 8), suggesting that binding
occurred through interactions with the HA-tagged ptDC-
SIGN molecules. These data indicate that the neck deletion
mutant may oligomerize, and that a determinant outside of
the repeat sequence may also participate in subunit inter-
actions of ptDC-SIGN.
Transmission of SIV by ptDC-SIGN deletion mutants
Next, we examined whether the ptDC-SIGN mutants
were able to transmit SIV to target cells (Fig. 6). AsFig. 5. Immunoblot analysis of differentially tagged ptDC-SIGN. 293T cells
were transiently cotransfected with wild type and mutant ptDC-SIGN
differentially tagged with an HA or myc epitope. Two days post-transfection,
cells were lysed and wild type and mutant ptDC-SIGN were immunopre-
cipitated with an anti-HA specific monoclonal antibody and protein-G
sepharose beads. Following SDS-12% PAGE, proteins were detected by
Western immunoblot using an anti-myc specific monoclonal antibody.
Procedures were as described in Materials and methods. Lane: (1)
untransfected cells; (2) pHM6/pCMVmyc; (3) wt ptDC-SIGN-HA/wt
ptDC-SIGN-myc; (4) control; (5) DNECK-HA/DNECK-myc; (6) control;
(7) wt ptDC-SIGN-HA/DNECK-myc; and (8) control. Immunoprecipita-
tions were performed with anti-HA and protein-G sepharose in lanes 1, 2, 3,
5, and 7. To control for nonspecific binding of ptDC-SIGN to protein-G
sepharose, lysates used for analysis in lanes 3, 5, and 7 were preincubated
with protein-G sepharose beads alone and analyzed in lanes 4, 6, and 8,
respectively.predicted, lower amounts of virus were detected 10 days
after transfer by the neck deletion mutant, DNECK78–224,
than by wild-type ptDC-SIGN. This reduced amount of
virus corresponded with low virus binding activity of the
DNECK78–224 mutant, further indicating that the neck
deletion mutant captured only a small amount of virus.
Surprisingly, the DCRD232–290 mutant failed to transfer
virus above background levels, although its SIV capture
activity was reduced by only 2.5-fold compared to wild-type
ptDC-SIGN. We also compared the amount of virus being
transferred after a single cycle of infection using a luciferase
reporter assay. However, we were unable to detect viral
infection significantly above background levels with either
mutant compared to wild-type ptDC-SIGN (data not
shown). Titration of the virus using the capture and transfer
assay indicated that wild-type ptDC-SIGN can capture and
transmit SIVeven when the amount of virus used for capture
is up to 500-fold less than that used for capture and
transmission by the DCRD232–290 mutant (data not
shown). Together, these data indicate that the amount of
virus transmitted by the mutant ptDC-SIGN molecules was
indeed small.
Reduced binding affinity is one mechanism that could
explain our observation that the DCRD232–290 mutant
could capture SIV but not transmit it. To address this, we
quantified virion binding to wild-type ptDC-SIGN and the
DCRD232–290 mutant with decreasing amounts of SIV
(Fig. 7). Binding by DCRD232–290 was similar to wild-
type ptDC-SIGN at high concentrations of SIV. However, at
low concentrations of virus, binding was significantly
reduced for DCRD232–290. These data suggest that virus
may dissociate from the DCRD232–290 mutant before it
can be transferred to target cells. Together, they reinforce the
Fig. 7. Binding of SIV to wild-type ptDC-SIGN and DC-SIGNDCRD232–290. 293T cells transiently transfected with wt ptDC-SIGN, DC-SIGNDCRD232–
290, or a control plasmid (pHM6) were incubated with various concentrations of SIVmne170 or DMEM complete, and the amount of virions bound to cells
was determined as in Fig. 1. The experiments were performed in triplicate and the data are representative of two independent experiments. The average amount
of p27gag bound to either wild-type ptDC-SIGN or DC-SIGNDCRD232–290 is shown as a percentage of that bound by these constructs at 10 ng p27gag F
SEM after correcting for background binding.
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viral infection.
ptDC-SIGN CRD site-directed mutants
To further characterize the regions of the CRD important
for ligand interactions, we mutated amino acid residues,
which based on the structure of the human DC-SIGN CRD,
are predicted to be involved in Ca2+ and mannose binding
(N326, V328, E331), disulfide bonding (C244), or located
within the second alpha helix of the CRD (I258, E275)
(Feinberg et al., 2001). FACS analysis using anti-DC-SIGN
MAbs against the CRD (8C1) and the neck domain (DC4)
revealed that five of the mutants were expressed at the cell
surface (Table 1). Detection by the anti-CRD MAb 8C1 was
reduced for each mutant compared to wild-type ptDC-
SIGN. Even with the anti-NECK MAb DC4, expression
of the mutants appeared to be lower than that of wild-type
ptDC-SIGN, particularly mutants N326D, V328G, and
E331Q. Mutants with a cysteine to alanine change at aminoTable 1
Expression of ptDC-SIGN and binding to ICAM-3 and SIV
Mutant 8C1 DC4 ICAM-3 Capture (%)
%a MFIb % MFI
WT 93.8 86.2 77.0 11.0 + 100 F 9.6
N326D 63.3 40.3 41.6 11.9  0
V328G 72.7 45.5 63.8 13.6  0
E331Q 66.7 35.1 46.2 9.1  0
E275P 78.6 43.0 70.4 11.1  78 F 15
E275L 76.0 26.8 69.8 11.8  89 F 7.2
a Percentage of cells positive for surface staining of ptDC-SIGN with the
indicated antibody.
b Mean fluorescent intensity.acid position 244 or a isoleucine to proline change at
position 258 were not detected with either antibody, and
therefore, were not likely expressed on the cell surface (data
not shown). In virion capture assays, mutants N326D,
V328G, E331Q did not bind to SIV. However, changing
residue E275 to either proline or leucine did not significant-
ly decrease virion capture compared to wild-type ptDC-
SIGN. Also, both mutants were capable of transferring virus
at levels similar to wild-type ptDC-SIGN (data not shown).
Interestingly, ICAM-3 did not bind to any of the mutants.
These results are consistent with those in Fig. 3, and they
provide additional evidence that SIV capture by ptDC-SIGN
occurs via high-mannose oligosaccharides in the viral en-
velope protein. The data also suggest that the second N-
terminal alpha helix is important for ICAM-3 binding but
not virion capture.Discussion
By performing a virion capture assay with different
ptDC-SIGN deletion mutants, we showed that the C-termi-
nal half of the CRD appears to be critical for capture of SIV.
This stretch of amino acids within the ptDC-SIGN CRD
shares high sequence identity with the Ca2+ and mannose
binding regions of the human DC-SIGN and DC-SIGNR
CRDs (Feinberg et al., 2001; Mitchell et al., 2001), suggest-
ing that carbohydrates in the viral glycoprotein are likely
recognized by ptDC-SIGN. In support of this interpretation,
virion binding activity was disrupted after deleting amino
acids 291–332, which included conserved residues (E331,
V328, and N326) that are important for human DC-SIGN
interactions with Ca2+ or mannose (Feinberg et al., 2001).
Furthermore, introduction of point mutations at each of
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conclusion is also consistent with our observation that SIV
binding to ptDC-SIGN is inhibited by mannan and EGTA.
Although an earlier study reported that deglycosylated
HIV gp120 could bind to human DC-SIGN, recent studies
have provided evidence that binding to DC-SIGN is depen-
dent on high-mannose structures in the HIV gp120 protein
(Geijtenbeek et al., 2002; Hong et al., 2002; Lin et al.,
2003). Our mapping of a virion capture determinant to the
region of the ptDC-SIGN CRD that is important for carbo-
hydrate recognition provides further evidence that virus
binding to ptDC-SIGN occurs through high-mannose struc-
tures. Furthermore, an Env deletion mutant of SIV did not
bind to ptDC-SIGN, indicating that the viral Env protein is
the major factor in viral particles mediating attachment to
ptDC-SIGN.
An earlier study of HIV-1 and ICAM-3 binding to human
DC-SIGN focused on the ligand binding site of the CRD
(Geijtenbeek et al., 2002). Here, we demonstrate that
mutants with the N-terminal segment of ptDC-SIGN CRD
either deleted or containing point mutations in the second
alpha helix could still capture SIV. However, these mutants,
like others that we tested, failed to bind ICAM-3. These data
suggest that the determinants necessary for binding SIV and
ICAM-3 are overlapping but distinct. One caveat of these
experiments is that we have used a recombinant human
ICAM-3. Identification of the pig-tailed macaque homolog
of ICAM-3 will be necessary to confirm that the binding
determinants are indeed different.
Deletion of the ptDC-SIGN neck region also resulted
in significant loss of virion capture activity. An earlier
study on human DC-SIGN also found that removal of the
neck region reduced virion capture and transfer (Pohl-
mann et al., 2001a). However, interpretation of the data
was confounded by low surface expression of the mutant.
Here, we demonstrated by FACS analysis that the level of
ptDC-SIGN neck deletion mutant at the cell surface was
similar to that of wild-type ptDC-SIGN, indicating that
low surface expression of the mutant was unlikely to
account for its poor capture activity. Alternatively, the
structure of the CRD may have been disrupted by the
deletion of the neck domain, thereby preventing efficient
capture of SIV. However, the anti-ptDC-SIGN MAbs, 8C1
and 11C1, used to detect surface expression of the ptDC-
SIGN neck deletion mutant, DNECK78–224, were pre-
viously shown to recognize a conformation dependent
epitope(s) in the CRD (Yu Kimata et al., 2002). These
data provide evidence that significant misfolding of the
CRD in the absence of the neck domain is unlikely to
account for poor virus binding capacity of the neck
deletion mutant.
Biochemical data suggest that DC-SIGN oligomerizes
into tetramers, where the neck region forms a stable a-
helical stalk that supports the CRD (Mitchell et al., 2001).
The data also show that the specificity of DC-SIGN
binding to glycopeptides with multiple oligosaccharidesis increased by the clustering of the CRDs into tetrads.
Although it may be that the ptDC-SIGN neck deletion
mutant, DNECK78–224, poorly binds SIV because it does
not oligomerize, this is unlikely because glycoproteins that
fail to oligomerize usually do not exit the endoplasmic
reticulum, and therefore, are not expressed at the cell
surface (Ellgaard and Helenius, 2003). Moreover, the neck
deletion ptDC-SIGN mutant was expressed at levels sim-
ilar to wild-type ptDC-SIGN, suggesting that it may still
oligomerize. Immunoprecipitation/immunoblot analysis
with differentially tagged wild type and ptDC-SIGN neck
deletion (ptDC-SIGNDNECK) constructs demonstrated
that the neck deletion mutant may associate with itself or
wild-type ptDC-SIGN. These data suggest that in addition
to the neck, other regions of ptDC-SIGN may contribute to
subunit interactions. One model consistent with our data is
that the neck may support proper clustering of the indi-
vidual CRD, thereby allowing efficient ligand binding.
This could explain why ICAM-3 binding to the ptDC-
SIGN neck deletion mutant, like virus binding, was dra-
matically reduced compared to binding to wild-type ptDC-
SIGN but reactivity of the anti-CRD MAb 8C1 was not
significantly affected.
Low virion transmission by the ptDC-SIGN mutants
occurred as a result of poor capture activity. This was
clearly evident with the neck deletion mutant, DNECK78–
224, which transmitted the small amount of virus that it
captured. However, the DCRD232–290 mutant failed to
transfer virus to permissive cells, although it bound a
greater amount of virus than DNECK78–224. One possi-
ble explanation for our observation is that the DCRD232–
290 mutant binds virus with reduced affinity. Indeed, we
found that at low virus concentrations, SIV binding was
quite poor compared to wild-type DC-SIGN. This suggests
that virus may dissociate from the DCRD232–290 mutant
before it can actually be transmitted to permissive cells.
Furthermore, it raises the possibility that the N-terminal
region of the CRD has a role in virion release. An
alternative explanation is that deletion of the N-terminal
region of the CRD disrupts internalization of virus by
ptDC-SIGN, thereby preventing subsequent transmission
of virus to permissive target cells. However, this model is
unlikely given that 293T cells do not internalize DC-SIGN
(Pohlmann et al., 2001a, 2001b). Moreover, a previous
study had demonstrated that internalization of virus may
not be necessary for transmission by DC-SIGN (Sol-
Foulon et al., 2002).
In summary, the results of this study provide evidence
that macaque DC-SIGN is functionally similar to human
DC-SIGN. Like HIV-1 binding to human DC-SIGN, the
interaction between SIV and pig-tailed macaque DC-SIGN
is carbohydrate-dependent and mainly mediated by the
viral envelope protein on virions. Importantly, the data
provide a basis for studies of the role of DC-SIGN in
transmission and pathogenesis in vivo using the SIV
macaque model.
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Cell lines and viruses
The 293T cell line was cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 2 mM glutamine, 100
U of penicillin/ml, and 100 Ag of streptomycin/ml (DMEM
complete). CEMx174 cells were cultured in RPMI 1640
supplemented with 10% heat-inactivated FBS, 2 mM glu-
tamine, 100 U of penicillin/ml, and 100 Ag of streptomycin/
ml (RPMI complete).
Virus stocks were generated as previously described (Yu
Kimata et al., 2002). Briefly, 293T cells were transfected
with plasmid proviral clones, washed with phosphate-buff-
ered saline (PBS) 24 h later, and then cultured in fresh
DMEM complete medium. The following day, supernatants
were collected, passed through 0.22-Am syringe filters, and
saved at 80 jC until used for infection experiments. The
amount of SIV p27gag antigen was quantified using a
commercial ELISA (Immunotech-Coulter, Miami, FL).
The titer of each virus stock was determined using the
previously described sMAGI assay (Chackerian et al.,
1995).
To generate an Env deletion mutant of SIVmne027, we
removed a 900-bp PstI to ClaI fragment from the coding
region of the Env SU sequence, and ligated the ends after
polishing the PstI and ClaI sites with T4 DNA polymerase
and Klenow, respectively. This procedure frameshifts and
adds stop codons that prevent translation of the Env TM
region. Mutations were confirmed by automated DNA
sequencing. Loss of infectivity was confirmed using the
sMAGI assay.
ptDC-SIGN deletion constructs
The ptDC-SIGN deletion constructs were created as
previously described (Yu Kimata et al., 2002). Briefly,
deletion mutations were introduced by PCR and the
mutants were cloned into the expression vector pHM6
(Roche), which adds a hemagglutinin (HA) tag to the
amino terminus of the translated protein. Following trans-
fection of the expression vectors into 293T cells, each
mutant protein could be detected by Western blot using an
anti-HA antibody and by fluorescence activated cell sort-
ing (FACS) analysis with anti-ptDC-SIGN monoclonal
antibodies. Additionally, the wild-type ptDC-SIGN se-
quence and ptDC-SIGNDNECK mutant were cloned into
pCMV-myc (Clontech). The proteins, ptDC-SIGN-myc and
ptDC-SIGNDNECK-myc, produced from these vectors are
myc-tagged at the amino terminus.
ptDC-SIGN CRD site-directed mutagenesis
Specificmutations were introduced into the CRD of ptDC-
SIGIN using the QuickChange Mutagenesis method (Stra-tagene, La Jolla, CA) according to manufacturer’s protocol.
The mutants were made using the ptDC-SIGN clone, p56-1,
and the following primer combinations: DC-SIGN N326D-F
(5V-CAAAGGAGAGCCCGACAATGTTGGGGAGG-3V)
and DC-SIGN N326D-R (5V-CCTCCCCAACATT-
GTCGGGCTCTCCTTTG-3V); DC-SIGN V328G-F (5V-
GAGAGCCCAACAATGGTGGGGAGGAAGAC-3V) and
DC-SIGN V328G-R (5V-GTCTTCCTCCCCACCATT-
GTTGGGCTCTC-3V); DC-SIGN E331Q-F (5V-CCAA-
CAATGTTGGGGAGCAGGACTGTGCGGAATTTAG-3V)
and DC-SIGN E331Q-R (5 V-CTAAATTCCGCA-
CAGTCCTGCTCCCCAACATTGTTGG-3V); DC-SIGN
C244A-F (5VGGACATTCTTCCAAGGAAACGCATATT-
TCATGTCTAACTCCCAGC-3V) and DC-SIGNC244A-R
(5VGCTGGGAGTTAGACATGAAATATGCGTTTCCTTG-
GCTGGGAGTTAGACATGAAATATGCGTTTCCTTG-
GAAGAATGTCC-3V); DC-SIGN I258P-F (5V-CTGGC-
ACGACTCCCCGACCGCCTGCCAGG-3V) and DC-SIGN
I258P-R (5V-CCTGGCAGGCGGTCGGGGAGTCGTGC-
CAG-3 V) ; DC-SIGN E275L-F (5 V-CGTCGTAAT-
CAAAAGTGCTTTGGAGCAGAACTTCCTACAGC-3V)
and DC-SIGN E275L-R (5V-GCTGTAGGAAGTT-
CTGCTCCAAAGCACTTTTGATTACGACG-3V); DC-
SIGN E275P-F (5V-CGTCGTAATCAAAAGTGCTCCG-
GAGCAGAACTTCCTACA-3V) and DC-SIGN E275P-R
(5V-TGTAGGAAGTTCTGCTCCGGAGCACTTTTGAT-
TACGACG-3V). Mutations were confirmed by sequencing,
and each mutant was inserted into the pcDNA3 expression
vector. Following transient transfection of 293T cells, the
cell surface expression of each mutant was examined by
FACS analysis with anti-DC-SIGN monoclonal antibodies
8C1 and DC4.
ptDC-SIGN capture assay
293T cells were transiently transfected with the appro-
priate ptDC-SIGN expression vector or a control vector
using the FuGene 6 reagent (Roche). Forty-eight hours post
transfection, the DC-SIGN-expressing cells were incubated
with the appropriate virus (5ng p27gag antigen) or DMEM
complete medium for 2 h at 37 jC. The cells were then
washed vigorously twice with DMEM complete medium
and once with PBS. The cell-associated virions were lysed
with 0.5% Triton-X and the amount of cell-associated
p27gag was quantified by a commercial SIV p27gag antigen
capture ELISA (Immunotech-Coulter).
To examine the inhibition of capture, a similar assay was
performed. However, the DC-SIGN-expressing 293T cells
were pretreated with mannan (20 Ag/ml), EGTA (5 mM), or
left untreated for 20 min at 37 jC. The cells were then
incubated with virus and the above protocol was followed.
Flow cytometry
To examine the expression of the ptDC-SIGN deletion
mutants, 293T cells transiently transfected with each dele-
J.E. Biggins et al. / Virology 324 (2004) 194–203202tion mutant were harvested and incubated with an anti-DC-
SIGN monoclonal antibody that recognizes the neck domain
(DC4; provided by R.W. Doms), an anti-ptDC-SIGN mono-
clonal antibody that recognizes the CRD (8C1; (Yu Kimata
et al., 2002), or an isotype control antibody for 30 min at 4
jC. The cells were then vigorously washed and incubated
with a fluorescently conjugated secondary antibody (Dako
Corp., Carpinteria, CA) for 30 min at 4 jC. Finally, the cells
were fixed in 1% paraformaldehyde and examined using a
FACScan analyzer (Becton Dickenson, San Diego, CA).
To investigate ICAM-3 binding by the ptDC-SIGN
deletion mutants, a similar FACS analysis was performed.
The transiently transfected cells were first incubated with
recombinant human ICAM-3 (R&D Systems, Minneapolis,
MN) or a control antibody for 30 min at 4 jC and then with
a fluorescently conjugated secondary antibody under the
same conditions.
Immunoprecipitation and immunoblot
293T cells were co-transfected with plasmids that express
HA- and myc-tagged versions of wild-type or mutant ptDC-
SIGN (wt ptDC-SIGN-myc and wt ptDC-SIGN-HA; ptDC-
SIGNDNeck-myc and ptDC-SIGNDNeck-HA; ptDC-
SIGNDNeck-myc and wt ptDC-SIGN-HA; or pCMV-myc
and pHM6 vectors). Forty-eight hours later, cells were
harvested, washed 1 with cold phosphate-buffered saline
(PBS), and lysed in lysis buffer containing 150 mM NaCl,
50 mM Tris–HCl, pH 7.9, 1% Igepal (NP40), 0.1 U of
aprotinin/ml, 1mM phenylmethylsulfonyl fluoride, and pro-
tease inhibitors (2 Ag pepstatin A, chymostatin, antipain,
and leupeptin/ml in PBS) for 10 min on ice with occasional
rocking. The lysates were clarified by brief centrifugation at
4 jC. For immunoprecipitation reactions, equal amounts of
protein lysates were incubated with 1 Ag of anti-HA
monoclonal antibody (Roche) for 1 h at 4 jC. Protein G-
sepharose was added and the lysates were incubated at 4 jC
for two additional hours. The immunoprecipitated protein-
bead complexes were pelleted by brief centrifugation at 4
jC, washed 4 with lysis buffer and resuspended in 2
sample buffer, heated at 95 jC for 5 min and subjected to
SDS-12% polyacrylamide gel electrophoresis (PAGE). Sep-
arated proteins were transferred to nitrocellulose membrane.
The myc-tagged proteins were detected with a 1:5000
dilution of horseradish peroxidase coupled anti-myc anti-
body (Invitrogen) by enhanced chemiluminescence (Amer-
sham Pharmacia).
ptDC-SIGN capture and transfer assay
293T cells were transiently transfected with either an
HA-tagged wild-type ptDC-SIGN expression vector or
pHM6 vector without insert using the FuGene 6 reagent
(Roche). Twenty-four hours post-transfection, the cells were
replated in a 96-well U-bottom plate at a concentration of
105 cells per well in 100 Al. The following day, the cellswere incubated with SIVmne170 (5ng p27gag antigen) or
DMEM complete medium for 2 h at 37 jC. The cells were
then washed vigorously three times with DMEM complete
medium and co-cultured with CEMx174 cells for a 2-week
period. At various time points, supernatants were collected
from each well and analyzed by antigen capture ELISA
(Immunotech-Coulter).Acknowledgments
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